ORMP | tickerfilter.com

Fundamental analysis

12%

Profitability 0%

Dept financing 9%

Liquidity 50%

Performance 15%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-1.02%

1 Month

-1.17%

3 Months

24.26%

6 Months

52.25%

1 Year

57.94%

2 Year

4.00%

Key data

Stock price

$3.38

P/E Ratio

0.00

DAY RANGE

$3.24 - $3.47

EPS

$1.03

52 WEEK RANGE

$1.82 - $3.76

52 WEEK CHANGE

$46.96

MARKET CAP

0.000

YIELD

N/A

SHARES OUTSTANDING

39.802 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

05-08-2025

BETA

1.01

PUBLIC FLOAT

AVERAGE 10 VOLUME

$242,646

AVERAGE 30 VOLUME

$177,054

Company detail

CEO: Nadav Kidron
Region: US
Website: oramed.com
Employees: 10
IPO year: 2007

Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its flagship product is the ORMD-0801, an oral ingestible insulin capsule. It is also developing an oral glucagon-like peptide-1 capsule.

ORMP - ORAMED PHARMACEUTICALS INC.